Search
Arthritis Clinical Trials in Houston, TX
A listing of 26 Arthritis clinical trials in Houston, TX actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 26
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Arthritis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Houston, Texas, currently has 26 active clinical trials seeking participants for Arthritis research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Gout Clinical Study
Recruiting
If you are struggling to manage gout flares, you know about the side effects of urate lowering treatments. Our clinical trials is looking to develop safer, more effective medicines to reduce uric acid and ease
symptoms. See if you are eligible to enroll for our rheumatic studies and receive payment of up to $1100. There is no obligation to take part and health insurance is not required.
symptoms. See if you are eligible to enroll for our rheumatic studies and receive payment of up to $1100. There is no obligation to take part and health insurance is not required.
Conditions:
Gout
Gout Flare
Acute Gout
Gouty Arthritis
Gout Attack
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
Recruiting
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis, Enteropathic Arthritis, Enteropathic Spondylitis
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.
The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Novel Research | Bellaire Location, Houston, Texas +3 locations
Conditions: Psoriatic Arthritis
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/02/2025
Locations: Arthrosi Investigative Site (601), Houston, Texas
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Study of GS-0272 in Participants With Rheumatoid Arthritis
Recruiting
The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA).
The primary objectives of this study are to assess the safety and tolerability of multiple ascending doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple doses of GS-0272, in participants with RA.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/01/2025
Locations: Accurate Clinical Research, Inc., Houston, Texas
Conditions: Rheumatoid Arthritis
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: UT Physicians Center for Autoimmunity, Houston, Texas
Conditions: Arthritis, Psoriatic
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
Recruiting
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Arthritis, Polymyalgia Rheumatica, Immune Checkpoint Inhibitors
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: UDL Clinical Research, LLC, Houston, Texas +4 locations
Conditions: Rheumatoid Arthritis
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
Recruiting
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD).
Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Accurate Clinical Research, Inc, Houston, Texas
Conditions: Rheumatoid Arthritis
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.
The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Accurate Clinical Research, Inc, Houston, Texas +1 locations
Conditions: Psoriatic Arthritis, Overweight or Obesity
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Accurate Clinical Research, Inc, Houston, Texas
Conditions: Rheumatoid Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments.
The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Biopharma Informatic | Hassan, Houston, Texas
Conditions: Psoriatic Arthritis
1 - 12 of 26